Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

February 28 -
March 1, 2014

Las Vegas, Nevada

Scientific Agenda

Friday, February 28, 2014

7:30 am

Breakfast and registration

8:00 am

Welcome and introductions

Session IA: Breast Cancer: Highlights from the San Antonio Breast Cancer Symposium

Session moderator: Ruth M. O’Regan, MD

8:05 am

Pre-session knowledge/competence polling using ARRAY

8:10 am

Screening & prevention
Christy A. Russell, MD

8:30 am

ER/PR-positive breast cancer
William J. Gradishar, MD, FACP

8:50 am

HER2-positive breast cancer
Julie R. Gralow, MD

9:10 am

Triple negative breast cancer
Debu Tripathy, MD

9:30 am

Panel discussion: Take home messages from SABCS plus Q&A
Leader: Ruth M. O’Regan, MD

9:45 am

Coffee break

Session IB: Breast Cancer: Challenges in Breast Cancer Management

10:05 am

ER/PR-positive, HER2+ breast cancer – Which target dominates the phenotype?
Ruth M. O’Regan, MD

10:20 am

Triple Negative Breast Cancer – Navigating the heterogeneity of TNBC without getting lost in the details
Debu Tripathy, MD

10:40 am

Management of HER2 over-expressed breast cancer in the adjuvant, neoadjuvant, and metastatic settings – Optimal utilization of available agents and clinical trials
Christy A. Russell, MD

11:00 am

Post-session knowledge/competence polling using ARRAY

11:05 am

Q & A Session

Session II: Gynecologic Oncology

11:15 am

Pre-session knowledge/competence polling using ARRAY

11:20 am

Maintenance therapy for ovarian cancer – Do the benefits outweigh the adverse events?
Bradley J. Monk, MD, FACOG, FACS

11:35 am

Novel targeted agents and angiogenesis inhibitors for ovarian cancer
Robert L. Coleman, MD

12:00 pm

Cervical Cancer – Evolution in the standards of care
Bradley J. Monk, MD, FACOG, FACS

12:20 pm

Post-session knowledge/competence polling using ARRAY

12:25 pm

Q & A session

12:30 pm

Lunch

Session III: Gastrointestinal Cancers

Session moderator: Axel Grothey, MD

1:30 pm

Patient stratification and treatment decision making in pancreatic adenocarcinom
Jordan D. Berlin, MD

1:50 pm

Novel targets and therapies for GI malignancies
David H. Ilson, MD, PhD

2:15 pm

Treatment algorithm for the management of advanced CRC through multiple lines of therapy
Axel Grothey, MD

2:40 pm

Case discussion and Q&A
Moderator: Axel Grothey, MD

3:15 pm

Coffee break

Session IV: Therapeutic Breakthroughs in Oncology

Session Moderator: James Epstein, MD

3:35 pm

Advances in the immunotherapy of solid tumors – Checkpoint inhibitors, vaccines and immune adjuvants, and combination Regimens
• Lung Cancer
Scott N. Gettinger, MD
• Renal Cell Cancer
Walter M. Stadler, MD, FACP
• Melanoma
Antoni Ribas, MD, PhD
• Colorectal Cancer
Jordan D. Berlin, MD

4:20 pm

Malignant melanoma – Selecting, sequencing, and combining therapeutic agents
Antoni Ribas, MD, PhD

4:40 pm

Management algorithms for differentiated and medullary thyroid carcinoma
Marcia S. Brose, MD, PhD

5:00 pm

Q & A session

5:05 pm

Adjourn

Saturday, March 1, 2014

7:30 am

Breakfast

8:00 am

Welcome

Session V: Genitourinary Malignancies

Session Moderator: Robert Dreicer, MD, MS, FACP, FASCO

8:05 am

Advances in the management of skeletal related events/metastases in prostate cancer
Robert Dreicer, MD, MS, FACP, FASCO

8:25 am

Controversies in prostate cancer
• Active surveillance - Good idea or bad idea
Eric A. Klein, MD
• Continuous versus intermittent androgen deprivation
Robert Dreicer, MD, MS, FACP, FASCO
• How to sequence the many novel agents for advanced CRPC
Charles J. Ryan, MD

8:55 am

Panel discussion and Q&A

9:10 am

Prostate cancer recurrence risk assessment and the role of genomic profiling and somatic mutational analysis
Charles J. Ryan, MD

9:30 am

Frontline therapy for advanced clear cell RCC – Should it be the same for everyone
Walter M. Stadler, MD, FACP

9:50 am

Case discussion and Q&A
Moderator: Robert Dreicer, MD, MS, FACP, FASCO

10:20 am

Coffee break

Session VI: Therapeutic Challenges in Oncology

Session Moderator: James Epstein, MD

10:40 am

Managing oxaliplatin-induced sensory neurotoxicity
Sandra E. Kurtin, RN, MS, AOCN, ANP-C

11:00 am

Q&A session

11:05 am

Therapy-related cardiac toxicity in cancer patients
Jean-Bernard Durand, MD

11:25 am

Q&A session

11:30 am

Carcinoma of unknown primary (CUP) - Three decades of evolution in diagnostic evaluation and management
Frank Anthony Greco, MD

11:55 am

Q&A session

12:00 pm

Lunch

Session VII: Thoracic Malignancies

Session moderator: Corey J. Langer, MD, FACP

 

 

 

 

1:00 pm

Pre-session knowledge/competence polling using ARRAY

1:05 pm

Adjuvant therapy for NSCLC – State of the art and ongoing clinical trials
Corey J. Langer, MD, FACP

1:25 pm

Genomics of Lung Cancer – Practical Implications
Ramaswamy Govindan, MD

1:45 pm

Management of EGFR-mutant NSCLC resistant to EGFR-TKI therapy
Anne Tsao, MD

2:10 pm

Management of ALK positive NSCLC – initial therapy and resistant disease
Ranee Mehra, MD

2:30 pm

Coffee break

2:50 pm

How I utilize mutational analysis in NSCLC adenocarcinoma to guide therapy
Anne Tsao, MD

3:10 pm

Role of c-MET and HSP90 Inhibitors in NSCLC
Ramaswamy Govindan, MD

3:30 pm

MEK Inhibitors and their potential role in relapsed NSCLC
Ranee Mehra, MD

3:50 pm

Squamous cell carcinoma – Oncologic drivers including FGFR and emerging therapies
Corey J. Langer, MD, FACP

4:15 pm

Post-session knowledge/competence polling using ARRAY

4:20 pm

Panel discussion and Q&A

4:45 pm

Adjourn